Celgene Careers NewsEmployer Directory Featured Listing, Feeds and Subscriptions

The latest Celgene careers news and job posts. Subscribe for daily updates to your inbox, mobile device and/or smartphone.

  Jobs Feed | Subscribe  

**Other Locations:** US- NJ- Summit East **Description** Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and deve...
Posted: January 21, 2018, 8:59 am
**Other Locations:** US- NJ- Summit East **Description** Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and deve...
Posted: January 21, 2018, 8:59 am
**Other Locations:** US- NJ- Summit East **Description** Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and deve...
Posted: January 21, 2018, 8:59 am
**Other Locations:** US- NJ- Summit East **Description** Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and deve...
Posted: January 21, 2018, 8:59 am
**Other Locations:** US- NJ- Summit East **Description** Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and deve...
Posted: January 21, 2018, 8:59 am

Viewing page 1 of 40|Next Page

  Newsfeed | Subscribe  

SUMMIT, N.J. (AP) — Biopharmaceutical company Celgene is buying the remainder of Juno Therapeutics Inc. that it doesn't already own in a deal valued at about $9 billion, which will help it develop medicines for patients with incurable blood cancer...
Posted: January 22, 2018, 4:06 am
(Reuters) - Celgene Corp (CELG.O) said on Monday it agreed to buy rest of Juno Therapeutics Inc (JUNO.O) for about $9 billion in cash to gain access to Juno’s pipeline of CAR-T cancer drugs. Celgene already owns 9.7 percent in Juno and will offer ...
Posted: January 22, 2018, 4:03 am
Celgene Corp said on Monday it would pay about $9-billion in cash to acquire the rest of Juno Therapeutics Inc and gain access to Juno's experimental gene therapy to treat cancer. The $9-billion represents an offer $87 per share to Juno's sharehol...
Posted: January 22, 2018, 4:03 am
Celgene agreed to buy rest of Juno Therapeutics it doesn't already own for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs. Celgene already owns 9.7 percent in Juno and will offer $87 per share. Shares of Juno Ther...
Posted: January 22, 2018, 3:56 am
Celgene Corporation (CELG) and Juno Therapeutics, Inc. (JUNO) today announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno. Under the terms of the merger agreement, Celgene will pay $87 per share in cash...
Posted: January 22, 2018, 3:46 am

Viewing page 1 of 2|Next Page